Trial · NCT06055465
Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
NCT06055465, Phase 2, Active not recruiting, Chinese University of Hong Kong
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer. Trials, record NCT06055465. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06055465
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer
- NCT number
- NCT06055465
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 37 participants, actual
- Lead sponsor
- Chinese University of Hong Kong
- Conditions
- Lung Cancer
- Interventions
- Sacituzumab Govitecan, Pembrolizumab
- First posted
- 2023-09-26
- Last updated
- 2026-06-18
Source ClinicalTrials.gov
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Pathological complete response (pCR) rate in the intention-to-treat population | 2 years | |
| Secondary | Resection rate after neoadjuvant SG and pembrolizumab combination: proportion of patients who undergo surgery with curative intent | 2 years | |
| Secondary | pCR rates in patients who undergo surgery | 2 years | |
| Secondary | Major pathological response (MPR) rate in the ITT population and in patients who undergo surgery: MPR is defined as less than 10% viable tumor cells in resected primary tumour specimen | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on neoadjuvant SG and pembrolizumab combination | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 while on adjuvant pembrolizumab | 2 years | |
| Secondary | Number of participants with treatment-related adverse events as assessed by CTCAE v5.0 first 30 days after surgery | 2 years | |
| Secondary | Objective response rate (ORR): rate of partial and complete response on CT scans according to RECIST criteria ver 1.1 | 2 years | |
| Secondary | Overall Survival | 2 years | |
| Secondary | 12 month and 24 month event-free survival (EFS) rate | 2 years |
1 to 10 of 11Source ClinicalTrials.gov
See all 11 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06055465
GET https://conductscience.org/api/trials/v1/NCT06055465/registered